Physician profile
Oscar Escobar
NPI 1164495404
$2,143.72
in general payments reported to CMS, 2019-2025
9 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2021: $88.31 · 2022: $206 · 2023: $307 · 2024: $366 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Education: $38.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.36 |
| Education | $38.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,279.66 | 2019-2024 | |
| Novo Nordisk INC | $361.78 | 2022-2025 | Sogroya |
| Biomarin Pharmaceutical INC. | $202.18 | 2021-2024 | Voxzogo 1.2mg |
| Tolmar, INC. | $175.83 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $86.13 | 2022 | |
| Chiesi USA, INC. | $21.49 | 2024 | Myalept |
| Xeris Pharmaceuticals, INC. | $16.65 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.